Our monthly Clarity in financial reporting newsletter informs you of key focus areas in financial reporting for the month: actions, developments, and dates.
Why does it matter? With the revised research and development regime in place for the financial year ending 30 June 2022, now is the time to ensure accounting outcomes are consistent with the changed aspects of the scheme.
A revised R&D tax offset regime, also known as the R&D Tax Incentive (RDTI), has taken effect for income years commencing on or after 1 July 2021, and will therefore be accounted for in annual financial statements for the year ending 30 June 2022.
The net tax benefit available under the scheme is limited to an increased $150 million annual expenditure cap. The R&D tax offset is available as either a refundable or non-refundable tax offset (applying a premium above the entity’s prevailing corporate tax rate), depending on whether the aggregated turnover of the claimant is less than $20 million (refundable) or $20 million and over (non-refundable).
The refundable R&D offset premium is set at 18.5% above the prevailing corporate tax rate which is the base tax rate of 25%, resulting in an R&D rate of 43.5%. The non-refundable offset base premium is set at 8.5% above the prevailing corporate tax rate (of 25% or 30%), with a 16.5% premium above the prevailing corporate tax rate for eligible R&D expenditure exceeding a defined 2% ‘R&D intensity threshold’.
The manner in which the ‘clawback’ mechanisms work has been altered and now are reflected through the entity’s income tax return in all cases.
When compared to the previous RFTI regime, the new regime may change some existing accounting policies and introduce additional accounting issues.
Our recent Clarity publication Accounting for the R&D tax offset:
Access the publication here.
Why does it matter? Ensure you are aware of the latest developments.
A summary of recent developments: